Sirolimus
- Generic Name
- Sirolimus
- Brand Names
- Fyarro, Hyftor, Rapamune
- Drug Type
- Small Molecule
- Chemical Formula
- C51H79NO13
- CAS Number
- 53123-88-9
- Unique Ingredient Identifier
- W36ZG6FT64
- Background
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria Streptomyces hygroscopicus, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive a...
- Indication
Sirolimus is indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. In patients at low-to moderate-immunologic risk, it is recommended that sirolimus be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn two to four months after transplantation. In pati...
- Associated Conditions
- Chordomas, Facial Angiofibroma, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Lymphangioleiomyomatosis (LAM), Renal Angiomyolipomas, Transplanted Organ Rejection, Metastatic malignant Perivascular Epithelioid Cell Neoplasms, Unresectable, locally advanced malignant Perivascular Epithelioid Cell Neoplasms
- Associated Therapies
- -
Comparison of Sirolimus to Tacrolimus for Long Term Therapy in Kidney Transplant With no Steroids
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 177
- Registration Number
- NCT00170053
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
- Conditions
- Interventions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 40
- Registration Number
- NCT00166712
- Locations
- 🇺🇸
Northwestern University/Northwestern Memorial Hospital, Chicago, Illinois, United States
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2012-03-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 105
- Registration Number
- NCT00146614
- Locations
- 🇺🇸
Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT00144703
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00144677
- Locations
- 🇺🇸
Dana-Farber Cancer Center, Boston, Massachusetts, United States
Efficacy and Safety of Sirolimus in Combination With Tacrolimus
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2005-12-01
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 190
- Registration Number
- NCT00141804
- Locations
- 🇩🇪
University Hospital Muenster, Muenster, Germany
Study Comparing Sirolimus With Cyclosporine in a Calcineurin Inhibitor (CNI)-Free Regimen in Kidney Transplant Recipients
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2013-02-08
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00137345
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 77
- Registration Number
- NCT00133887
- Locations
- 🇫🇷
Hôpital Edouard Herriot - Service de Dermatologie, Lyon, France
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
- Conditions
- First Posted Date
- 2005-08-23
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT00133367
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00129961
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.